<DOC>
	<DOCNO>NCT00925015</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetic interaction Human Anti-Human Antibody dalotuzumab combination cetuximab irinotecan patient advance metastatic colorectal cancer Japan .</brief_summary>
	<brief_title>Phase I Study Dalotuzumab ( MK0646 ) Combination With Cetuximab Irinotecan Colorectal Cancer Patients ( 0646-016 )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patient Is 20 Years Of Age Or Older Patient Has A Histologically Or Cytologically Confirmed Colorectal Cancer Patient Has Previously Failed Both Irinotecan And Oxaliplatin Containing Regimens And Should Have Progressed On Or Within 3 Months Of Completing Their Last Line Of Therapy With Objective Radiological Evidence Of Progression As Verified By Previous Radiologic Scans Patient Must Have Adequate Organ Function Patient Has Had Chemotherapy , Radiotherapy , Or Biological Therapy Within 4 Weeks Prior To Initial Dosing On This Study Or Whose Toxicities From Agents Administrated 4 Weeks Earlier Have Not Resolved To At Least Grade 1 Or Baseline Patient Has Experienced Intolerable Toxicity To Irinotecan Therapy Patient Has Prior Exposure To Igf1r Inhibitors Or Egfr Inhibitors ( E.G . Cetuximab ) Patient Is Concurrently Using Growth Hormone ( Gh ) , Or Growth Hormone Inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>